Nandita Khera is an Oncology physician affiliated with WinnMed. OpenAlex indexes 372 publications with 5,932 citations (h-index 45); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13400 E Shea Blvd
Scottsdale, AZ 852595452
Telephone
480-301-8000Provider last certified this registry record 10 Sept 2020.
Clinical trials
- Evaluation of a Couple-Based Physical Activity Intervention
Sponsor: Mayo Clinic
- Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma
Sponsor: Mayo Clinic
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20253 payments
- Incyte CorporationProgram year20232 payments
- Celgene CorporationProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
69.3%PD-1 inhibitor36.3%Pembrolizumab53%Nivolumab47%Part B, office-administered≥25 patientsCD38-directed Cytolytic Antibody17.3%Daratumumab100%Part B, office-administered≥27 patients+ 6 more classes in this area
Metabolism & gastrointestinal
19.8%Other antiemetics16.6%Fosaprepitant100%Part B, office-administered≥33 patientsSerotonin-3 Receptor Antagonist3.1%Palonosetron hcl54%Ondansetron hydrochloride46%Part B, office-administered≥54 patients+ 1 more class in this area
Anti-infectives
4.3%Human Immunoglobulin G4%Immune globulin100%Part B, office-administered≥25 patientsShort-acting sulfonamides0.1%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Mayank Sardana, MD
WinnMed
Rakesh Suri, MD
WinnMed
Jorge Rakela, MD
WinnMed
Hugo Vargas, MD
WinnMed
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”